Merck KGaA reports higher profits on strong volumes across its businesses

Company expects strong organic growth in sales, EBITDA in 2022

Merck KGaA restructures life science business to support long-term growth

Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services

Merck KGaA appoints Global R&D Head & CSO for healthcare business sector

Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer

Merck KGaA to acquire biopharma CDMO Exelead for $780 million

The transaction is expected to close in the first quarter of 2022

Merck doses first patient in Phase 3 trial of novel antibody-drug conjugate for metastatic colorectal cancer

The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments

MilliporeSigma lands exclusive 5-year deal to test Genetix Biotherapeutics gene therapies

The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy

Manthan 2026 wraps up, spotlighting India’s life sciences & clinical research future

India in the Changing Landscape of Life-Sciences Research & Development

China approves first-in-class TGCT drug, marking global first for pimicotinib

Lilly, Novo Nordisk closer to deal with Trump administration to slash obesity drug prices to $149/month

The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies

MilliporeSigma partners with Promega to advance 3-D cell drug discovery technologies

Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies